Quectel Releases New 4G/5G, LPWA and GNSS Antennas to Help Customers Optimize Device Performance
11.7.2023 12:00:00 EEST | Business Wire | Press release
Quectel Wireless Solutions, an IoT global solutions provider, proudly announces the launch of an exciting line-up of antennas designed to meet a wide spectrum of requirements:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230711943901/en/
Quectel releases new 4G/5G, LPWA and GNSS antennas to help customers optimize device performance (Photo: Business Wire)
- YEMN926J1A: This state-of-the-art 9-in-1 5G screw mount combo antenna is at the forefront of technology. It offers superior performance for 5G networks and is designed with a screw mount for easy installation.
- YECW000N1A: This external antenna is specifically optimized for low power wide area (LPWA) networks. It provides excellent connectivity for LPWA applications and ensures reliable and efficient communication.
- YEGT000W8A: Our advanced active global satellite navigation system (GNSS) L1 and L5 antenna, ideal for precise positioning and timing. It offers enhanced accuracy and reliability for GNSS applications.
These antennas showcase cutting-edge technology and are designed to meet the demands of today's connectivity requirements.
“We’re proud to launch these three new antennas which further add to our range of 4G/5G, LPWA and GNSS antennas,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “Antennas are often overlooked during device development but it’s important to enable developers with antennas that can be optimized for their specific use cases and provide them with the performance they need to meet their application needs. These new antennas provide customers with even greater opportunities to optimize their solutions as they build a smarter world.”
The YEMN926J1A is a 9-in-1 5G screw mount combo antenna optimized for 5G and 4G networks. It includes a GNSS antenna and measures 167mm x 57mm. Both RoHS and REACH compliant, the combo antenna also is IP67 and IP69K rated which means it offers complete protection against ingress of dust and airborne particles as well as protection against water and liquids up to and including immersion in up to 1m of water. The IP69K rating also means the product can withstand washdown pressure of 80-100 bar in phases of 14-16 l/min at temperatures of up to 80°C.
The ultra-wide-band 5G/4G antenna box provides broad coverage from 600-6,000MHz while offering support for 3G and 2G networks as well at Cat-M and NB-IoT. The antenna is designed to work with various ground plane sizes or in free space for ease of integration with nine cable connections on the antenna as required and cable length options from 300mm to 5000mm, terminated with SMA connectors. The screw mount omnidirectional antenna is easy to install with maximized durability and is compatible with Quectel's RM520x series modules.
The YECW000N1A external antenna offers high efficiency with a low profile and is optimized for LPWA connections. With dimensions of 149.73mm x 49.91mm x 35.5mm, the antenna operates in the 450-470MHz, 700-960MHz and 1710-2690MHz frequency bands. The external 4G antenna covers the main LTE bands and is also compatible with 3G, 2G and LPWA bands.
RoHS compliant, the YECW000N1A has been carefully designed so it is minimally influenced by the internal environment of devices it is connected to. This enables it to deliver better efficiency, radiation and gain while providing optimized performance for customers’ products. A further advantage is that Quectel offers flexible installation options with custom cable lengths and connectors available.
Completing Quectel’s latest antenna introductions, the YEGT000W8A is an active GNSS L1 and L5 antenna that supports the 1164-1189MHz and 1559-1606MHz frequency bands. With dimensions of 65mm x 45mm, the GNSS antenna is RoHS and IP67 compliant.
The YEGT000W8A offers a choice of configurations to guarantee the most suitable polarization type and was specifically developed for 5G RAN timing. Quectel’s positioning products support single-band or multi-band operation modes to meet various high- precision positioning requirements of customers’ products. Customized connector types and cable lengths are provided according to customers’ requirements.
In addition to providing antennas, Quectel also provides comprehensive antenna design support which includes simulation, testing and manufacturing for custom antenna solutions to meet customers’ specific application needs. This support, allied to innovative antennas, helps enable customers to optimize device performance.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas, services and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230711943901/en/
Contact information
Media: media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom